Back to results
US 10,000,563 B2Granted
Monoclonal antibodies that bind both IL-17A and IL-17F
AssigneeZymoGenetics, Inc.
InventorsStephen R. Jaspers, Scott R. Presnell, Monica J. Huber
Life of this patent
Estimating the term…
Abstract
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
Claims3
A pharmaceutical composition comprising:
- (a) a cross-reactive humanized monoclonal antibody that binds to both IL-17A (SEQ ID NO:2) and IL-17F (SEQ ID NO:4);
- and
- (b) a pharmaceutically acceptable vehicle, carrier, or excipient,
- wherein the antibody inhibits the binding of both IL-17A and IL-17F to IL-17RC, wherein the antibody binds to the same epitope as the antibody produced by the hybridoma deposited with the American Type Culture Collection having ATCC Patent Deposit Designation PTA-7988, and
- wherein the composition is suitably formulated for parenteral, subcutaneous or intravenous administration to a human.
2 more elements
Dependencies are inferred from the claim text.